BSTE Biosite (MM)

European and U.S. Clinicians to Present at European Stroke Conference Recognized Stroke Experts to Provide Clinical Data on the Triage(R) Stroke Panel SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated (NASDAQ:BSTE) today announced that European and U.S. research clinicians will present data from clinical studies conducted using Biosite's Triage Stroke Panel at the 14th Annual European Stroke Conference, to be held May 25 through 28, 2005 in Bologna, Italy at the Palazzo della Cultura et dei Congressi. The symposium, "A New Paradigm in Emergency Stroke Diagnosis," will take place May 27, 2005 from 6:00 p.m. to 7:30 p.m. (local), or 12:00 p.m. to 1:30 p.m. Eastern Daylight Time, and will be webcast through Biosite's website at http://www.biosite.com/. Dr. Werner Hacke, University of Heidelberg will chair the symposium. Other key opinion leaders to be featured in the symposium include Dr. Daniel Laskowitz, Duke University Medical Center; Dr. Joan Montaner, Vall d'Hebron Hospital, Barcelona, Spain; Dr. Christian Berger, University of Heidelberg; Dr. Patrik Michel, University Hospital, Lausanne, Switzerland; Dr. Philip Bath, University of Nottingham, United Kingdom; Dr. Edward Jauch, University of Cincinnati College of Medicine; Dr. Marc Freysz, University Hospital, Dijon, France; Dr. Patrick Sauval, Service d'Aide Medicale Urgente, Paris, France; Dr. Salvatore Di Somma, Sant'Andrea Hospital, Rome, Italy; and Dr. Marco Fiorelli, University Hospital La Sapienza, Rome, Italy. Biosite filed a Premarket Approval Application for the Triage Stroke Panel with the U.S. Food and Drug Administration (FDA) in December 2004. Data from 15 clinical sites and approximately 2,000 patients were included in the clinical studies submitted to the FDA. The data that will be presented at the symposium are a subset of the data submitted to the FDA. A link to the live audio webcast and presentations can be accessed through the Biosite website, http://www.biosite.com/. The Biosite presentation will be archived on the website for 21 days in the Investor and Media section under Events Calendar. About Biosite Incorporated A leader in the drive to advance diagnosis, Biosite Incorporated is a research-based company dedicated to the discovery and development of novel protein-based diagnostics that improve a physician's ability to diagnose debilitating and life-threatening diseases. Through combined expertise in diagnostic discovery and commercialization, Biosite is able to access potential markers of disease, identify proteins with high diagnostic utility, develop and commercialize products and educate the medical community on new diagnostic approaches, thereby benefiting patients. Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in more than 50 international markets for toxicology screening and diagnosis of infectious and cardiovascular disease. Information on Biosite can be found at http://www.biosite.com/. Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words "will"; "believes"; "should"; "intends"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Risks and uncertainties include risks that FDA clearance for the Triage Stroke Panel will be delayed or rejected, uncertainties related to the regulatory scrutiny that will be applied to the Triage Stroke Panel's MultiMarker Index(TM) feature, risks regarding the discovery and product development process generally, and risks associated with the commencement of manufacturing the Triage Stroke Panel on a commercial scale. Other risks and uncertainties that may impact the Company's business generally include risks associated with the introduction of competitive products from companies with greater capital and resources, expansion or development of a direct sales effort in domestic and international markets, and risks and expenses associated with litigation, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, regulatory changes, competitive pressures on average selling prices, and the other risks including those detailed in the Company's most recent Annual Report on Form 10-K, and other SEC filings. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Copies of the Company's public disclosure filings are available from the Investor Relations department. Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered trademarks of Biosite Incorporated. The Company's logo is a trademark of Biosite Incorporated. DATASOURCE: Biosite Incorporated CONTACT: Nadine Padilla, Vice President, Corporate and Investor Relations of Biosite Incorporated, +1-858-455-4808, ext. 3187, Web site: http://www.biosite.com/ Company News On-Call: http://www.prnewswire.com/comp/116737.html

Copyright